GSK Hit With Justice Subpoena, More Lawsuits Over Avandia

GlaxoSmithKline (GSK) has revealed that it is under investigation from the Justice Department and several states for actions related to the development and marketing of its diabetes drug Avandia. The company is responding to a subpoena from Justice as well as civil investigative demands from numerous state attorneys general, the company said Thursday. GSK took a $2.36 billion charge against its earnings in the second quarter of this year to settle litigation related to Avandia (rosiglitazone), but now it has been hit with more lawsuits over the drug, Andrew Witty, GSK’s CEO, said in a conference call.
Drug Industry Daily